Rgenta

Rgenta Therapeutics is a biotechnology company that develops small-molecule drugs targeting traditionally "undruggable" targets by building an RNA-related target discovery and screening platform. These targets are often located in critical regulatory programs and signaling pathways of disease progression, making them ideal targets for drug intervention. Rgenta's unique technology platform can mine vast amounts of genomic data to identify RNA targets that can be selectively acted upon by small molecules and design small-molecule glues to modulate spliceosomes and regulate interactions between proteins and RNA. Rgenta is developing a series of orally administered small-molecule drugs targeting RNA for the treatment of cancer and neurological disorders.